Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of nakiolunsai injection for CD19-positive relapsed or refractory acute lymphoblastic leukemia
CTR20202493Phase 2Active
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Jan 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of inaticabtagene autoleucel in acute lymphoblastic leukemia (ALL), B cell acute lymphoblastic leukemia (B-ALL), sponsored by Juventas Cell Therapy Ltd.. Started Jan 2021; status: active.
02
Drugs
inaticabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20202493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202493.